PROGNOSIS IN PATIENTS WITH ST SEGMENT ELEVATION MYOCARDIAL INFARCTION, IN REGARD TO THE PRESENCE OF TYPE 2 DIABETES MELLITUS AND SELECTED TREATMENT STRATEGY IN THE ACUTE PERIOD

Aim. To assess the results of endovascular revascularisation in patients with acute myocardial infarction (AMI) and ST segment elevation (STEMI), in regard to the presence of Type 2 diabetes mellitus (DM-2), in the real-world clinical settings. Material and methods. The study included 423 STEMI patients, with or without concomitant DM-2. In the DM-2 group (n=77, 18,20%), percutaneous coronary intervention (PCI) was performed in 35 individuals (45,5%); in participants without DM-2, the respective figure was 54,91% (n=190). The follow-up period lasted for one year. The adverse long-term prognosis included repeated non-fatal MI and/or stroke, cardiac death, unstable angina, and decompensated heart failure (combined end-point). Results. In patients who underwent PCI, the presence of DM-2 did not affect substantially (p>0,05) the incidence of adverse clinical outcomes: it reached 28,57% (n=10) in participants with STEMI and DM-2 and 30,53% (n=58) in STEMI patients without DM-2. However, among individuals who did not undergo PCI, DM-2 was associated with increased incidence of the combined end-point: 52,38% (n=22) among those with STEMI and DM-2 vs. 42,95% (n=67) among those with STEMI only. Repeated interventions due to stent thrombosis (n=2; 5,71%) or stent restenosis (n=4; 11,43%) were non-significantly more frequent among patients with DM-2, compared to the non-diabetic patients (1,05% (n=2) and 3,68% (n=7), respectively). Therefore, PCI in STEMI patients with DM-2 substantially improved the long-term prognosis, halving the incidence of the combined end-point. By contrast, this incidence was reduced only by 1,5 among patients who did not undergo PCI. To summarise, the presence of DM-2 is associated with adverse long-term prognosis only in STEMI patients who do not undergo PCI. Conclusion. The presence of DM-2 significantly aggravates long-term prognosis in AMI patients who do not undergo PCI.

1. Dedov I.I., Aleksandrov A.A. Statins and myocardial microvascular ischemia. Consillium medicum 2004; 6 (9):620–4. Russian (Дедов И. И., Александров А.А. Статины и «микрососудистая ишемия» миокарда. Consilium medicum 2004; 6 (9):620–4).

2. Keith A.A., Steg P.G., Kim A.E. et al. For the GRACE investigators decline in rates of death and heart failure in acute coronary syndromes. JAMA 2007; 297:1892–900.

3. Eagle K.A., Goodman S.G., Avezum A. et al. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet. 2002; 359:373–7.

4. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). (ACC/AHA 2009 STEMI/PCI Guidelines Focused Update). Related Slide Set. http://content.onlinejacc.org/

5. Ganukov V.I., Protopopov A.V. Acute coronary syndrome. Krasnoyarsk 2005; 41–52. Russian (Ганюков В.И., Протопопов А.В. Острый коронарный синдром. Красноярск 2005; 41–52).

6. Morgan K.P., Kapur A., Beatt K.J. Anatomy of coronary disease in diabetic patients: an explanation for poorer outcomes after percutaneous coronary intervention and potential target for intervention. Heart 2004; 90:732–8.

7. Sianos G., Morel M.A., Kappetein A.P. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroInterv 2005; 1:219–27.

8. Donahoe M.S., Stewart G.C., McCabe C.H. et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298:765–75.

9. Furnary A., Wu Y., Booking S. Effect of hyperglycemia and continuous intravenous insulin infusio n on outcomes of cardiac surgical procedures:thePortland DiabeticProject. EndocrPract 2004; 10 (2):21–33.

10. Erlikh A.D., Gratsiansky N.A. The RECORD Registry. Treatment of patients with acute coronary syndromes in hospitals with and without possibilities to perform invasive coronary procedures. Cardiology 2010; 7:8–14.Russian (Эрлих А.Д., Грацианский Н.А. Регистр РЕКОРД. Лечение больных с острыми коронарными синдромами в стационарах, имеющих и не имеющих возможности выполнения инвазивных коронарных процедур. Кардиология 2010; 7:8–14).

11. Erlikh A. D., Gratsiansky N. A. The RECORD Registry. Independent registry of acute coronary syndromes RECORD. Patients’ profiles and treatment before the hospital discharge. Atherothrombosis 2009; 1 (2):105–19. Russian (Эрлих А. Д., Грацианский Н. А. Регистр РЕКОРД. Независимый регистр острых коронарных синдромов РЕКОРД. Характеристика больных и лечение до выписки из стационара. Атеротромбоз 2009; 1 (2):105–19).

12. Alter D. A., Ko D. T., Newman A. et al. Factors explaining the under-use of reperfusion therapy among ideal patients with ST-segment elevation myocardial infarction. Eur. Heart J. 2006; 27:1539–49.

13. Fei G. Z., Huang Y. H., Swedenborg J. et al. Oxidised LDL modulates immuneactivation by an IL-12 dependent mechanism. Atherosclerosis 2003; 169:77–85.

14. Gilbert J., Raboud J., Zinman B. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care 2004; 27:990–4.

15. Mathew V., Gersh B. J., Williams B. A. et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004; 109:476–80.